Skip to Content

391 G (Carbidopa and levodopa extended release 50 mg / 200 mg)

Pill imprint 391 G has been identified as Carbidopa and levodopa extended release 50 mg / 200 mg.

Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 50 mg / 200 mg is not a controlled substance under the Controlled Substance Act (CSA).

Carbidopa and levodopa extended release 50 mg / 200 mg 391 G
Carbidopa and levodopa extended release 50 mg / 200 mg 391 G
Discount Card Promo
Carbidopa and levodopa extended release
Imprint:
391 G
Strength:
50 mg / 200 mg
Color:
Purple
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Dopaminergic antiparkinsonism agents
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Manufacturer:
Global Pharmaceuticals
National Drug Code (NDC):
00115-3911
Inactive Ingredients:
hydroxypropyl cellulose
magnesium stearate
FD&C Blue No. 2
FD&C Red No. 40

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide